Magazine Article | March 1, 2021

Inside The Planning Of Audentes' Future Manufacturing Facility

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Audentes Therapeutics’ Sanford, NC, facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational this year.

Donald Wuchterl, Audentes’ SVP of technical operations, and Don Mather, executive director, manufacturing & operations site head at Audentes, give some details on the planning stages, equipment needs, challenges, and status of this massive project.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader